Category: Accesswire

  • Altigen Announces First Quarter Fiscal Year 2026 Earnings Call Information

    Altigen Announces First Quarter Fiscal Year 2026 Earnings Call Information

    NEWARK, CALIFORNIA / ACCESS Newswire / January 14, 2026 / Altigen Technologies (OTCQB:ATGN), a leading Silicon Valley-based Microsoft Cloud Communications Solutions provider, today announced it will report its first quarter 2026 financial results after the close of regular market trading on Tuesday, February 3, 2026. The Company will also hold a conference call to discuss the results at 4 p.m. Eastern Standard Time (1 p.m. PT)

    When: Tuesday, February 3, 2026 at 4:00 p.m. Eastern Standard Time (1:00 p.m. PT).

    Dial In:

    Toll Free: 888-506-0062
    International: 973-528-0011
    Participant Access Code: 363285

    Participants will be greeted by an operator and asked for the access code. If a caller does not have the code, they can reference the company name.

    Webcast: https://www.webcaster5.com/Webcast/Page/2183/53480

    Teleconference Replay: Available until Tuesday, February 10, 2026

    Toll Free: 877-481-4010
    International: 919-882-2331
    Replay Passcode: 53480

    Webcast Replay: Available until Sunday, May 3, 2026

    https://www.webcaster5.com/Webcast/Page/2183/53480

    About Altigen Technologies

    Altigen Technologies (OTCQB:ATGN) is focused on driving digital transformation in today’s modern workplace.  Our Cloud Communications solutions and Technology Consulting services empower companies of all sizes to elevate customer engagement, increase employee productivity and improve operational efficiency. We’re headquartered in California, and our operations are strategically located in five countries spanning three continents. For more information, call 1-888-ALTIGEN or visit our website at www.altigen.com.

    Contact: ir@altigen.com

    SOURCE: Altigen Technologies

    View the original press release on ACCESS Newswire

  • The Scion Advisory Services Team Joins CannonDesign’s Growing Education and Student Life Consultancy

    The Scion Advisory Services Team Joins CannonDesign’s Growing Education and Student Life Consultancy

    Providing services ranging from market studies to full housing master plans and P3 transactional support, Scion Advisory Services has collaborated with more than 300 North American campuses, solidifying its reputation as a leader in student living. The team’s expertise bolsters CannonDesign’s rapidly growing consulting practice, anchored by Blue Cottage of CannonDesign, with a broadened ability to drive strategic impact for education institutions at every scale.

    NEW YORK CITY, NY / ACCESS Newswire / January 14, 2026 / CannonDesign and The Scion Group are pleased to announce that Scion Advisory Services, a premier education consultancy in North America, has become part of CannonDesign.

    Dedicated to helping colleges and universities optimize their residential programs, the Scion Advisory Services team offers deep experience in housing planning, residential life administration, real estate finance, and program and asset management.

    Providing services ranging from market studies to full housing master plans and P3 transactional support, Scion Advisory Services has collaborated with more than 300 North American campuses, solidifying its reputation as a leader in student living. The team’s expertise bolsters CannonDesign’s rapidly growing consulting practice, anchored by Blue Cottage of CannonDesign, with a broadened ability to drive strategic impact for education institutions at every scale.

    “The Scion Advisory Services team has proven itself an agent for positive impact, helping higher education institutions shape meaningful student life outcomes for a quarter of a decade. They make our company stronger immediately,” said Juliet Rogers, Ph.D., MPH, MAPL, president of Blue Cottage of CannonDesign and Chief Strategy Officer of CannonDesign. “Scion Advisory Services equips us to offer higher education institutions end-to-end advisory services at a moment when they are facing numerous shifting forces and market changes.”

    Among Scion Advisory Services’ current and past clients are some of the most dynamic education institutions in the United States, including the California State University System, the University of Arkansas, the University of Maine System, and the University of Nevada Las Vegas. The team has also delivered work for over 50 Canadian colleges and universities, including the University of Ottawa and University of Calgary.

    Beyond Scion Advisory Services’ deep student life portfolio, the group also has extensive experience in structuring and guiding successful public-private partnerships (P3s). As more institutions turn to P3s to deliver successful projects, Scion Advisory Services’ expertise in financial structuring, risk allocation and stakeholder alignment is paramount.

    “Our advisory practice has been at the center of our business identity for our entire 26-year history,” said Robert Bronstein, CEO of The Scion Group. “It is important to us that this group be able to offer our decades of expertise to the higher education sector as part of an equally highly regarded team going forward. Having worked extensively with CannonDesign in the past, we are confident this evolution is an ideal way to continue that legacy as part of a growing consultancy offering.”

    CannonDesign and Scion Advisory Services previously partnered on housing and residence life planning projects at the University of Rochester, University of Rhode Island, the University of Massachusetts and Florida State University. The two groups’ history of successful collaboration demonstrates that the addition of Scion Advisory Services will be a strong complement to CannonDesign’s existing design and consulting services.

    “Scion Advisory Services is a highly regarded partner across the education ecosystem, already delivering visionary work on campuses of every type,” remarked Brad Lukanic, AIA, LEED AP, CEO of CannonDesign. “This move represents our shared commitment to helping our clients reach new heights and set new precedents in education design and strategy.”

    Scion Advisory Services will operate under its current name for an interim period before fully integrating into CannonDesign’s education consulting practice within Blue Cottage of CannonDesign, working in close partnership with the firm’s higher education planning and design teams.

    The addition of Scion Advisory Services is the latest in a series of strategic moves advancing CannonDesign’s evolution as a design firm capable of helping clients solve challenges of nearly any type across the built environment and beyond. Other recent acquisitions include Jenkins•Peer Architects, a Charlotte-based design firm; Christner Architects, a St. Louis-based design firm; Yellow Brick Consulting, a leader in healthcare transition and activation; and The Clarient Group, experts in smart-building consulting.

    Media Contact
    Chris Whitcomb
    CannonDesign
    cwhitcomb@cannondesign.com

    SOURCE: CannonDesign

    View the original press release on ACCESS Newswire

  • Genomate Health Expands Global Footprint With Acquisition of Oncompass Medicine

    Genomate Health Expands Global Footprint With Acquisition of Oncompass Medicine

    Genomate Health, the U.S.-based precision medicine company transforming cancer care through its proprietary computational reasoning technology, today announced its acquisition of Oncompass Medicine. The move marks a major milestone in Genomate Health’s global expansion and establishes a strong operational base in Europe.

    CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 14, 2026 / Genomate Health, the U.S.-based precision medicine company transforming cancer care through its proprietary computational reasoning technology, today announced its acquisition of Oncompass Medicine. The move marks a major milestone in Genomate Health’s global expansion and establishes a strong operational base in Europe.

    Our priority is to ensure that precision oncology delivers its full potential for every patient,” said Nabil Hafez, MS, MBA, CEO of Genomate Health. “This acquisition allows us to close the gap between advanced molecular diagnostics and real-world patient access. It combines the advanced computational reasoning technology of Genomate® with Oncompass Medicine’s clinical expertise to deliver the best cancer care worldwide.”

    Founded in Budapest in 2003, Oncompass Medicine has been a leader in personalized oncology for more than two decades. The company has supported patients and healthcare providers across Europe with advanced precision oncology services, pioneered some of the first companion diagnostic tests for precision oncology in 2003, and was among the first to implement next-generation sequencing-based tumor profiling in routine clinical care in 2008.

    “We are not just expanding our geographic footprint; we are building a unified, single precision oncology company that has pioneered all three major technological breakthroughs needed to realize the promise of precision oncology – from the first diagnostic tests to molecular tumor profiling tests and the first clinically validated computational methods solution,” said Dr. Istvan Petak, Founder and Chief Scientific Officer of Genomate Health. “This strategic step fulfills my dream of reuniting with the team I had led for many years to develop the first companion diagnostic tests.”

    Under the agreement, Oncompass Medicine contributes its well-established operations, logistics, clinical expertise, and a deeply rooted market presence in Europe. Scientific and clinical continuity will be led by Dr. Istvan Petak, Founder and Chief Scientific Officer of Genomate Health, who will also serve as Managing Director of Oncompass Medicine, supported by a multidisciplinary team of oncologists, molecular diagnostics specialists, and data scientists. Together, the organization significantly expands Genomate Health’s international reach and operational capacity, with the transaction expected to be revenue-accretive and immediately strengthen the company’s European footprint.

    This creates a unified European framework for Genomate Health, accelerating the company’s mission to make precision oncology accessible worldwide. By combining Oncompass Medicine’s operational excellence with Genomate Health’s computational reasoning technology, the company is building a fully integrated precision oncology platform that transforms complex molecular data into actionable treatment decisions at scale.

    The acquisition reinforces Genomate Health’s leadership position in precision oncology and opens the door to new collaborations with global health systems, life science organizations, and cancer research institutions. To maintain continuity and trust across its existing networks, the Oncompass Medicine brand will continue in Hungary under the name Oncompass Medicine, a Genomate Health company.

    The acquisition builds on a strong foundation of recent milestones, including the kickoff of U.S. operations at the 2025 SelectUSA Investment Summit, a $2 million raise to support clinical rollout, and GenomeWeb’s designation of the company as 2025’s “Best Place to Work”.

    About Genomate Health

    Genomate Health Inc. is a medical technology company based in Cambridge, MA, developing computational and diagnostic solutions for personalized medicine. Its flagship product, Genomate®, is the first clinically validated universal computational reasoning model to predict response to multiple targeted therapies by analyzing each patient’s unique combinations of genetic alterations and biomarkers. Genomate® delivers the first computational reasoning solution that moves beyond stratified medicine to realize the true promise of precision oncology, ranking therapies based on the complete genetic makeup of the patient’s tumor. Genomate Health is a graduate of the Mayo Clinic Accelerate Program, a CancerX initiative founding member, and part of the Precision Medicine Coalition.

    Learn more: www.genomate.health

    About Oncompass Medicine

    Founded in 2003 in Budapest, Oncompass Medicine is a pioneer in precision oncology, integrating molecular diagnostics, advanced bioinformatics, and oncology decision-support tools to guide personalized cancer therapy. The company has been at the forefront of applying molecular diagnostics in solid tumors as companion diagnostics in 2003, next-generation sequencing in 2008, and mathematical modelling to identify effective targeted treatments for patients as early as 2014, earning international recognition for its innovations in personalized medicine. Starting January 2026, it operates as Oncompass Medicine, a Genomate Health company, serving as Genomate Health’s diagnostic service provider in Europe.

    Learn more: www.oncompass.hu

    Contact Information

    Alina Luchian
    Head of Marketing & Brand, Genomate Health Inc.
    alina.luchian@genomate.health

    SOURCE: Genomate Health

    View the original press release on ACCESS Newswire

  • CSuite Financial Partners Contributes CFO Perspective to Groundbreaking White Paper on Private Equity and Personal Injury Law Firms

    CSuite Financial Partners Contributes CFO Perspective to Groundbreaking White Paper on Private Equity and Personal Injury Law Firms

    SAN JOSE, CA / ACCESS Newswire / January 14, 2026 / CSuite Financial Partners, a leading provider of interim and fractional CFO services, announced today its contribution to a newly released white paper from the Private Equity Legal Alliance (PELA) focused on private equity investment in personal injury law firms.

    The white paper, “Building Ethical, Value-Focused Partnerships: How Personal Injury Law Firms Can Engage Private Equity to Unlock Capital, Fuel Growth, and Create Rewarding Exits,” provides a comprehensive roadmap for personal injury firm owners evaluating private equity investment, recapitalization or strategic partnerships under emerging Alternative Business Structure (ABS) and Management Service Organization (MSO) models.

    CSuite Financial Partners contributed a finance and CFO-focused perspective, addressing how law firms can prepare for institutional capital by building investor-grade financial reporting, controls and governance – often well in advance of a transaction.

    “Many personal injury firms have strong economics but lack the financial infrastructure private equity expects,” said Timi Okah, CEO of CSuite Financial Partners. “This paper helps founders understand what investors actually look for – clean accrual financials, cash flow visibility, normalized compensation and disciplined reporting – and how to prepare without compromising professional independence or ethics.”

    The publication is PELA’s first major thought leadership release and brings together expertise from across law, legal ethics, private equity and finance. Contributors include senior professionals from Holland & Knight, Samson Partners Group, Aprio Legal and CSuite Financial Partners.

    CSuite’s contribution focuses on the CFO’s role in a PI-PE transaction, including:

    Transitioning founder-led firms from cash-basis practices to GAAP-ready accrual accounting

    Establishing monthly close processes, forecasting discipline and board-level KPIs

    Preparing for quality-of-earnings reviews

    Preparing cash flow forecasts and establishing working capital requirements

    Helping founders understand how compensation normalization and governance affect valuation and deal structure

    “Private equity doesn’t just invest in results – it invests in systems, controls and predictability,” Okah added. “Even firms that never pursue a transaction benefit from adopting these disciplines. They become stronger, more resilient businesses.”

    The white paper also explores consolidation trends in personal injury law, ethical considerations of MSO and ABS structures, operational readiness and lessons from other professional services industries such as accounting and healthcare.

    The white paper is available for free download here.

    About CSuite Financial Partners

    CSuite Financial Partners provides interim and fractional CFO services to founder-led and private equity-backed companies. The firm specializes in financial leadership during growth, transition and transaction, including mergers, acquisitions, recapitalizations and post-close integration. CSuite helps leadership teams build investor-grade finance functions and create durable enterprise value.

    About the Private Equity Legal Alliance

    The Private Equity Legal Alliance (PELA) is a consortium of advisors focused on helping law firms and investors navigate the evolving landscape of ownership, capital and professional ethics. PELA delivers legal, financial and operational expertise to support ethical and sustainable partnerships in the modern legal economy.

    Press Inquiries:
    Timi Okah
    President and CEO
    CSuite Financial Partners
    tokah@ravixgroup.com
    (408) 216-0656

    SOURCE: CSuite Financial Partners

    View the original press release on ACCESS Newswire

  • Vero To Attend 2026 AFSA Vehicle Finance Conference & Expo In Las Vegas

    Vero To Attend 2026 AFSA Vehicle Finance Conference & Expo In Las Vegas

    CEO John Mizzi and COO Isaac Zafarani to join senior auto finance leaders at Bellagio as the industry tackles risk, technology, and the next era of vehicle lending

    NEW YORK, NY / ACCESS Newswire / January 14, 2026 / Vero Technologies today announced its participation in the American Financial Services Association’s 2026 Vehicle Finance Conference & Expo, taking place February 1-5, 2026 at the Bellagio Hotel in Las Vegas, Nevada. Co‑Founders CEO John Mizzi and COO Isaac Zafarani will represent Vero throughout the conference, meeting with lenders, captives, and technology partners focused on the future of auto finance.​

    Hosted by AFSA, the Vehicle Finance Conference is the flagship gathering for leaders across the vehicle lending ecosystem, with programming that spans industry trends, workforce strategy, customer experience, fraud, AI, compliance, and dealer collaboration. Senior executives, regulators, and service providers will share perspectives on the forces reshaping origination, servicing, and dealer relationships in a tech‑driven market.​

    Vero’s leadership team will use the event to connect with auto finance leaders who are modernizing wholesale programs with better data, automation, and integrated workflows. With the auto finance market continuing to wrestle with credit risk, pricing pressure, and rising expectations from both dealers and consumers, Vero’s modular platform is designed to help lenders adapt without ripping out existing cores or compromising on control.​

    “AFSA’s Vehicle Finance Conference is where the people shaping this market actually get in the same room,” said John Mizzi, CEO and Co‑Founder of Vero Technologies. “Our conversations in Las Vegas will focus on how lenders can use orchestration, workflow automation, and dealer‑friendly tools to manage risk while still saying ‘yes’ more often to the right paper.”

    About Vero
    Vero provides an end-to-end SaaS and servicing platform designed to streamline wholesale, supply chain, rental and fleet financing. The modular platform supports every function across a lenders organization with process automation, analytics, and workflow management systems. Vero enables lenders to grow efficiently, reduce manual work, and enhance borrower experiences.

    For more information, visit www.vero-technologies.com

    Contact: Jason Bartz, press@vero-technologies.com, 404-383-7048

    SOURCE: Vero Finance Technologies

    View the original press release on ACCESS Newswire

  • GridAI and the New Operating Reality of the Electric Grid

    GridAI and the New Operating Reality of the Electric Grid

    BOCA RATON, FL / ACCESS Newswire / January 14, 2026 / For decades, managing the electric grid was largely a planning exercise. Operators forecast demand, built capacity, and adjusted slowly as conditions evolved. That model worked in an era when consumption patterns were predictable and infrastructure expansion could keep pace with growth.

    That operating reality no longer exists.

    The modern grid is now shaped by forces that compress time, increase volatility, and leave little margin for error. Artificial intelligence workloads fluctuate by the hour, electrification introduces new and uneven demand, and distributed energy assets behave dynamically rather than uniformly. Together, these shifts have moved grid management away from long-range planning and toward continuous operation.

    This is the environment in which GridAI Technologies Corp. (NASDAQ:GRDX) is positioning itself, aligned with a grid that can no longer be managed periodically but must instead be managed continuously.

    From Forecasting to Live Operations

    Traditional grid management relied on forecasts updated infrequently and acted upon conservatively. Operators planned for peak demand, built buffers into the system, and accepted inefficiencies as the cost of reliability. That approach assumed demand changed gradually and infrastructure could be adjusted over time.

    Today’s demand behaves very differently. AI-driven data centers ramp usage rapidly, EV charging patterns shift with pricing and incentives, and weather-dependent generation introduces variability on the supply side as well. The grid increasingly behaves like a live system rather than a static one, requiring decisions to be made in real time rather than weeks in advance.

    As a result, the distance between planning and execution has collapsed. Grid management is no longer a periodic task supported by forecasts. It has become a continuous operational process, where responsiveness matters as much as capacity.

    Grid intelligence emerges naturally in this context, not as an upgrade layered on top of legacy systems, but as a requirement for operating under modern conditions. That’s important.

    Why Human-Led Control Is No Longer Sufficient

    As grid dynamics accelerate, the limits of manual control become increasingly clear. Human operators are highly effective at managing known conditions and responding to isolated events, but they are not designed to continuously optimize complex, distributed systems that change minute by minute.

    The constraint is not expertise, but velocity. When load profiles shift across thousands of nodes, when price signals fluctuate in real time, and when reliability depends on constant coordination, decision-making must occur faster than human intervention alone allows.

    In this environment, software transitions from a support function into a control mechanism. Automation is not about replacing people, but about enabling decisions at a speed and scale that humans cannot sustain on their own. Grid intelligence becomes the connective layer linking data, assets, and action in real time.

    This shift is not theoretical or optional. It is an operational response to the way the grid now behaves.

    GridAI as an Operating Layer, Not a Tool

    Within this new operating reality, GridAI is positioning itself not as a feature or occasional optimization tool, but as an operating layer. Its role is to support continuous orchestration of demand, storage, and generation, rather than providing periodic insight or static recommendations.

    That distinction matters. Tools are used when needed. Operating layers are relied upon constantly.

    By embedding forecasting, coordination, and optimization into daily operations, GridAI aligns with how the grid must now be run. The platform is designed to respond to live conditions, adjust behavior dynamically, and support ongoing decision-making rather than fixed planning cycles.

    For enterprise customers, this approach supports operational resilience in the face of volatility. For utilities, it offers a way to maintain reliability without waiting for infrastructure expansion. For investors, it signals alignment with a structural shift in how critical systems are managed and controlled.

    The value lies not only in what is optimized, but in how consistently and reliably those optimizations occur.

    Early Alignment With a Structural Shift

    Operating model changes rarely announce themselves clearly. They emerge gradually as constraints make older approaches less effective. Organizations that adapt early often gain familiarity, integration depth, and operational confidence that compound quietly over time.

    The electric grid is now in the midst of such a shift. As continuous operation replaces static planning, platforms that support real-time orchestration become foundational rather than optional. Switching costs rise as systems integrate more deeply into workflows, and familiarity becomes a competitive advantage.

    GridAI’s positioning reflects this reality. Rather than attempting to retrofit legacy models, it is aligning with how the grid is increasingly operated. That alignment matters to customers navigating volatility and to investors looking for companies positioned at the right layer of change.

    Being early in an operating shift is not about being first to market. It is about being aligned before adaptation becomes unavoidable.

    A Different Lens on Grid Intelligence

    Grid intelligence is often discussed in terms of technology features or market size. A more meaningful lens is operational behavior, how systems are actually run and where decision-making authority resides.

    The grid is becoming more dynamic, more constrained, and more central to economic activity. Managing it now requires continuous awareness, rapid coordination, and software-driven control. Planning alone is no longer sufficient.

    GridAI’s relevance flows from that reality. Its role is defined less by innovation headlines and more by operational fit within a grid that must function in real time.

    As the grid’s operating model evolves, the platforms embedded within it will shape how efficiently, reliably, and flexibly power is managed. That shift is already underway.

    GridAI is positioning itself within that shift, not by predicting it, but by operating in it.

    About GridAI Technologies Corp
    GridAI Technologies Corp is a publicly listed company on the Nasdaq. The Company is a diversified technology and life sciences company advancing opportunities at the intersection of artificial intelligence and energy infrastructure following its acquisition of Grid AI, Inc. In addition to its GridAI operations, the Company (formerly Entero Therapeutics Inc.) continues to advance its late clinical-stage biopharmaceutical program focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

    Forward-Looking Statements
    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding strategic benefits of the acquisition, market opportunities, product capabilities, stockholder approval of the transaction, Nasdaq’s approval of an initial listing application, if any, and future operating results. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Important factors include, among others, our business strategy; the risk that regulatory or third-party approvals are delayed or not obtained; integration challenges; market adoption; competitive dynamics; macroeconomic and energy-market conditions; and other risks detailed from time to time in the Company’s SEC filings. The Company undertakes no obligation to update forward-looking statements.

    Accuracy & Disclosure Statement: Disclosure & Disclaimer
    Hawk Point Media Group, LLC (“HPM”) has been engaged by IR Agency, Inc. to provide press release, editorial, digital media, and consulting services related to GridAI Technologies Corp. As compensation for these services, HPM has received $10,000 USD via wire transfer to create sponsored content for GridAI Technologies Corp. The term of this engagement commenced on January 9, 2026, and concludes on January 16, 2026, unless extended by mutual agreement. Due to this compensation arrangement, the content herein should be considered sponsored content.

    The information contained in this publication is based on sources believed to be reliable, including publicly available filings, company disclosures, and official website materials, and is accurate to the best of our knowledge at the time of publication. This content is provided for informational purposes only and does not constitute investment advice, an offer to sell, or a solicitation to buy any securities. At the time of publication, Hawk Point Media Group, LLC does not own, buy, sell, or trade securities of the companies discussed and holds zero shares of GridAI Technologies Corp. or its former entity, Entero Therapeutics, Inc Any reproduction, redistribution, or syndication of this content must include this disclosure in its entirety.

    This disclosure is made in accordance with Section 17(b) of the Securities Act of 1933, the Federal Trade Commission’s Endorsement Guides, and other applicable regulations governing sponsored investment-related content.

    Contact email for this release: info@hawkpointmedia.com

    SOURCE: GridAI Technologies Corp

    View the original press release on ACCESS Newswire

  • Tresic Launches Intelligence Cloud to Help CSPs and MSPs Turn UCaaS/CCaaS Into “Connectivity + Intelligence” – With 2X+ Revenue Potential

    Tresic Launches Intelligence Cloud to Help CSPs and MSPs Turn UCaaS/CCaaS Into “Connectivity + Intelligence” – With 2X+ Revenue Potential

    New white-label platform analyzes 100% of customer conversations and delivers tasks, alerts, coaching, and executive insights in minutes – designed and priced for the SMB customers service providers support.

    DENVER, COLORADO / ACCESS Newswire / January 14, 2026 / Tresic today announced the launch of the Tresic Intelligence Cloud, a conversation intelligence and automation platform built for communications service providers (CSPs) and managed service providers (MSPs) that sell into the SMB market. Service providers can white-label Tresic and layer it on top of existing SIP, UCaaS, and CCaaS offers to instantly deliver differentiated AI-powered services – without building new infrastructure or changing how customers work.

    For many service providers, voice has become a race to the bottom. At the same time, the most valuable customer intelligence is still trapped inside everyday calls and messages – and most organizations can only review a small fraction of interactions. Tresic Intelligence Cloud changes that by capturing and understanding every customer conversation and turning it into action: follow-ups, escalations, policy checks, coaching, and executive-level insights.

    “Service providers shouldn’t have to choose between ‘commodity connectivity’ and risky, expensive AI projects,” said Kevin Nethercott, CEO of Tresic. “Tresic gives CSPs and MSPs a fast, white-label way to deliver high-value intelligence services that customers can feel the same day – while creating a new control point above connectivity.”

    Intelligence, Actioned: 100% coverage, fast deployment, built for SMB

    The Tresic Intelligence Cloud is a vCon-first, open platform designed to keep conversation data portable, interoperable, and protected. It delivers three core product pillars:

    • Co-Pilots – turnkey applications that turn conversations into action

      • After Call Co-Pilot: automatic post-call summaries, action items, and CRM-ready follow-ups

      • First Alert Co-Pilot: 100% conversation monitoring and instant alerts for churn risk, compliance issues, escalations, and urgent needs

      • Script Coach Co-Pilot: automated scoring and coaching across 100% of conversations

    • Insights Hub – executive-level trends, anomaly detection, and natural-language search across conversations

    • Developer Studio – APIs and tools for providers and builders to embed conversation intelligence and automation anywhere, with built-in privacy features such as redaction

    Tresic is engineered for rapid time-to-value. Service providers can integrate using multiple paths (including sending existing call data/recordings, sending vCons, or direct integration) and move from pilot to production quickly.

    A high-margin attach that can double – or more – the value of the installed base

    Tresic’s service provider model is designed to help CSPs and MSPs increase revenue per customer by packaging conversation intelligence as an add-on to UCaaS/CCaaS offers – with SMB-accessible pricing and a straightforward path to expansion.

    In early deployments and use cases:

    • One service provider saved two customer accounts within two weeks after executives received alerts about issues that never made it into the CRM.

    • Customers have identified and closed training and security gaps using real examples captured from day-to-day customer conversations.

    “SMBs don’t want another dashboard – they want outcomes,” said Robert Galop, CPO of Tresic. “We designed Tresic to make the action automatic: capture the signal, route it to the right person, and trigger the next step with evidence attached.”

    Partner momentum and a channel-first go-to-market

    Tresic is going to market through CSPs and MSPs, enabling providers to bring new AI-driven offers to customers quickly under their own brand.

    “Service providers are uniquely positioned to deliver conversation intelligence because they already sit closest to the conversation layer,” said Jason Goecke, CTO of Tresic. “With the Tresic Intelligence Cloud, partners can ship new intelligence experiences in days – and build differentiated vertical solutions without needing to assemble a complex AI stack.”

    Jon Brinton, CRO at Crexendo, added:
    “Crexendo is focused on helping our partners expand beyond classic unified business communications with offers their customers will immediately value. Tresic adds an AI-empowered intelligence layer that’s fast to deploy, easy to package, and built for real-world service provider operations. We see significant potential for partners to improve stickiness and grow revenue while delivering meaningful additional value to their customers.”

    Availability

    The Tresic Intelligence Cloud is available now for CSPs and MSPs in North America, with EU and APAC availability in mid-2026. Service providers interested in a white-label partner program can request a briefing and onboarding plan.

    About Tresic

    Tresic delivers Intelligence, Actioned. The Tresic Intelligence Cloud captures conversations across voice and messaging and automatically turns them into tasks, alerts, coaching, and insights – helping businesses move faster, serve customers better, and operate with less friction.

    Learn more at https://tresic.cloud

    CONTACT:

    Robert Galop
    Chief Product Officer
    robert@tresic.cloud

    SOURCE: Tresic

    View the original press release on ACCESS Newswire

  • CORAS Welcomes Maj. Gen. (Ret.) Jack J. Catton Jr. to Board of Advisors

    CORAS Welcomes Maj. Gen. (Ret.) Jack J. Catton Jr. to Board of Advisors

    Air Force modernization and requirements leader to help scale IL5-secure agentic AI decision intelligence for budgets, readiness, and mission execution

    MCLEAN, VIRGINIA / ACCESS Newswire / January 14, 2026 / CORAS, the only IL5-authorized Agentic AI Decision Intelligence platform in the Department of War (DoW), today announced that Major General (Ret.) Jack J. Catton, Jr. has joined its Board of Advisors.

    Catton brings decades of operational and enterprise defense experience spanning requirements, modernization investment planning, operational test, and joint war planning. In the U.S. Air Force, he concluded his career as Director of Requirements, Headquarters Air Combat Command, where he managed requirements and system capabilities, and drove operational evaluation of new and modified systems. He also was Chair of the Combat Air Forces Requirements Oversight Council for modernization investment planning.

    “Major General Catton has sat exactly where DoW leaders sit-balancing mission outcomes, modernization agendas, and investment tradeoffs while prioritizing readiness,” said Dan Naselius, President and CTO of CORAS. “His operational credibility and requirements expertise will be critical to maintaining relevance and excellence in our decision intelligence. CORAS customers rely on us to move faster, make complex decisions with data, leverage GARY LLM to optimize time and reduce toil, all while improving efficiency without sacrificing security or governance.”

    Catton added, “Modernization is won or lost in the space between requirements, resources, and execution. CORAS is tackling that problem directly bringing trusted data, decision structure, and secure agentic AI into the workflows where leaders make the calls that shape readiness.”

    Across more than 31 years of service, Catton served as a command pilot and Fighter Weapons School instructor, commanded at squadron/group/wing levels, and held senior roles across the Air Staff, NATO Staff, and Joint Staff. His career also included command of the 53rd Wing, responsible for operational test and evaluation of Air Force combat aircraft and associated tactics, avionics, and electronic combat capabilities.

    Following active duty, Catton served as Vice President for Air Force Systems at The Boeing Company, responsible for senior Air Force relationships and collaboration on requirements and capability needs, including program strategies and engagement to support full funding for major initiatives such as T-7A and F-15EX. He now leads Catton Consulting, advising innovative technology companies on effective collaboration with the U.S. Government.

    CORAS and its Agentic Agent GARY operate at IL5 and FedRAMP High in government environments including NIPR and SIPR, offering profound ROI and 10-50+x productivity. Agencies can acquire CORAS and GARY through GSA, NASA SEWP, SBIR Phase III, Tradewinds AI Marketplace, Carahsoft, and AWS partner channels. Learn more at www.coras.ai.

    Media Relations: Rebecca Churchill, Ph: 703-214-0076, v-rebecca.churchill@coras.ai

    SOURCE: CORAS

    View the original press release on ACCESS Newswire

  • Bonk, Inc. Kicks Off 2026 with 40% Surge in Daily Revenue Velocity; BONK.fun Generates Over $1.5 Million in First 11 Days

    Bonk, Inc. Kicks Off 2026 with 40% Surge in Daily Revenue Velocity; BONK.fun Generates Over $1.5 Million in First 11 Days

    Revenue Pace Accelerating Significantly vs. Record December Levels; Company Highlighted as Trading at Significant Discount to Tangible Asset Value

    SCOTTSDALE, ARIZONA / ACCESS Newswire / January 14, 2026 / Bonk, Inc. (Nasdaq:BNKK) today released a corporate update detailing what we believe to be a record-breaking start to the fiscal year. Driven by a sharp resurgence in the price of the BONK digital asset and a decisive shift in market dominance toward the BONK.fun platform, the Company’s primary revenue engines are currently outperforming internal projections for 2026.

    To kickstart the new fiscal year and address the Company’s accelerating momentum, Mitchell Rudy (a.k.a. Nom), Bonk, Inc. Board Director and core contributor, provided the following commentary on the strategic “flight to quality” occurring in the market and the current dislocation between the Company’s stock price and its asset value.

    Mitchell Rudy Commentary:

    “We entered 2026 with a clear goal: to prove that a community-first ecosystem could outperform the ‘wild west’ legacy platforms. We believe the data from the first 11 days of January confirms that this shift is happening faster than even we anticipated.

    “We set an internal ‘North Star’ for 2026 of maintaining a revenue floor of $100,000 per day on the BONK.fun platform. In the first 11 days of January, we didn’t just hit that floor-we smashed through it, generating over $1.5 million in total revenue, averaging roughly $136,000 per day. This is beating our own aggressive targets by 36%. While we saw a massive spike to start the year, what excites me most is that the daily volume has settled at a new, higher baseline.

    “This growth is being driven by a ‘Flight to Quality.’ As other platforms face scrutiny for bad actors and extractive practices, creators and traders are migrating to BONK.fun because it is built on transparency and community alignment. We are seeing leadership from major decentralized projects, like WLFI and USD1, look to our metrics as the new benchmark for health in the ecosystem.

    “However, the most important message for our shareholders today is about value.

    “Right now, Bonk, Inc. holds approximately $29 million in liquid assets-roughly $4 million in cash and $25 million in BONK digital assets. On top of that vault, we own the majority revenue interest in a platform that is currently pacing assuming current similar results, for over $18 million a year in pure cash flow to us.

    “When you do the simple math, you see a company trading at a significant discount to the sum of its parts. We have the cash, we have the growing treasury, and we have the operating engine that is printing revenue. Our job now is simple: keep executing, keep accumulating assets, and let the sheer weight of these financials close that valuation gap.”

    The Company also noted that the price of the BONK digital asset has seen a strong resurgence to start the year, appreciating from approximately $0.000008 to $0.000013. This price action acts as a force multiplier for Bonk, Inc., rapidly expanding the Net Asset Value (NAV) of the treasury holdings accumulated throughout the prior year.

    About Bonk, Inc. Bonk, Inc. (Nasdaq:BNKK) is a company evolving to bridge the gap between traditional public markets and the digital asset ecosystem. Through its subsidiary BONK Holdings LLC, the Company executes a strategy focused on acquiring revenue-generating assets within the decentralized finance space. The Company also operates a growing beverage division holding the patented Sure Shot and Yerbaé brands.

    Investor Relations Contact: Phone: 888.257.8061 Email: investors@bonkdat.com

    Forward-Looking Statements: This press release contains forward-looking statements. Such statements are subject to risks and uncertainties, and actual results could differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the performance of BONK digital assets, the operational success of the beverage division, market volatility, and other risks detailed in Bonk, Inc.’s filings with the Securities and Exchange Commission. The Company assumes no obligation to update forward-looking statements.

    SOURCE: Bonk, Inc.

    View the original press release on ACCESS Newswire

  • Aspire Biopharma Announces Reverse Stock Split

    Aspire Biopharma Announces Reverse Stock Split

    ESTERO, FL / ACCESS Newswire / January 14, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced a reverse stock split of its issued and outstanding common stock, par value $0.01 per share, at a ratio of one (1) share of common stock for every forty (40) shares of common stock, that will become effective as of 12:01 a.m. (Eastern Time) on January 16, 2026 (the “Effective Date”). The Company’s common stock will begin trading on a split-adjusted basis when the market opens on January 16, 2026. At the Company’s Special Meeting of Stockholders held on November 4, 2025, the Company’s stockholders approved a proposal to authorize a reverse stock split of the Company’s Common Stock, at a ratio within the range of 1-for-5 to 1-for-40. The Company’s board of directors approved a 1-for-40 reverse split ratio, and on January 15, 2026, the Company will file a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect the reverse stock split effective January 16, 2026. The Company’s common stock will continue to trade on The Nasdaq Capital Market under the stock ticker “ASBP” but will trade under the new CUSIP number 738920 206.

    The reverse stock split is being implemented to ensure the Company meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

    As a result of the reverse stock split, each forty (40) pre-split shares of common stock outstanding will automatically combine into one (1) new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 158.8 million shares to approximately 4.0 million shares without taking into account fractional shares. No fractional shares will be issued as a result of the reverse stock split. All fractional shares will be rounded up to the nearest whole share on an individual participant level. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity (other than as a result of the rounding of shares to the nearest whole share in lieu of issuing fractional shares).

    The Company’s transfer agent, Colonial Stock Transfer Company, Inc., which is also acting as the exchange agent for the reverse split, will send instructions to stockholders of record who hold stock certificates regarding the exchange of their old certificates for new certificates, should they wish to do so. Stockholders who hold their shares in brokerage accounts or “street name” are not required to take action to implement the exchange of their shares.

    About Aspire Biopharma Holdings, Inc.

    Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

    For more information, please visit www.aspirebiolabs.com

    Safe Harbor Statement

    This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and

    developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; Aspire’s acetylsalicylic acid sublingual powder, 162 mg (OTASA) is an investigational new drug and has not been approved for marketing for any indication, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

    Aspire Biopharma Holdings, Inc.

    Contact

    PCG Advisory
    Kevin McGrath
    +1-646-418-7002
    kevin@pcgadvisory.com

    SOURCE: Aspire Biopharma Holdings, Inc.

    View the original press release on ACCESS Newswire